77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

• Yun Zhang,
• Xin Li,
• Hongming Pan,
• Yoon-Koo Kang,
• Chia-Jui Yen,
• Ming-Mo Hou,
• Kun-Ming Rau,
• Ying Yuan,
• Xiaopeng Ma,
• Xikun Wu,
• Jong-Seok Lee,
• Cunjing Yu,
• Katie Wood

Affiliations

Yun Zhang

1 Clinical Medicine Department, Fujian Health College, Fuzhou, China

Xin Li

2 Department of Rheumatology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China

Hongming Pan

Aff4 0000 0004 1759 700Xgrid.13402.34Sir Run Run Shaw Hospital, College of MedicineZhejiang University Hangzhou China

Yoon-Koo Kang

Aff6 0000 0004 0533 4667grid.267370.7Asan Medical CenterUniversity of Ulsan College of Medicine Seoul South Korea

Chia-Jui Yen

5 National Cheng Kung University Hospital, Tainan, Taiwan

Ming-Mo Hou

9 Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan

Kun-Ming Rau

13 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Ying Yuan

4 The Cancer Institute Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, China

Xiaopeng Ma

7Beigene (Beijing) Co., Ltd., Beijing, China

Xikun Wu

6Beigene (Shanghai) Co., Ltd., Shanghai, China

Jong-Seok Lee

4National University Bundang Hospital, Seongnam-si, Korea, Republic of

Cunjing Yu

7BeiGene (Beijing) Co., Ltd., Beijing, China

Katie Wood

8BeiGene USA, Inc., San Mateo, CA, USA